MOUD Buprenorphine Subli denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issued This Denial

Aetna's "not FDA-approved" denial for sublingual buprenorphine (used as Medication for Opioid Use Disorder, or MOUD) is almost always a coding or routing error — or a confusion between formulations. Sublingual buprenorphine products indicated for opioid dependence treatment have held FDA approval for many years, and federal parity and anti-discrimination law strongly limits an insurer's ability to single out MOUD for coverage barriers that would not apply to treatments for other chronic conditions.

## Why This Denial Is Appealable

If your claim was denied on "not FDA-approved" grounds, the denial letter should identify the specific product code or indication Aetna flagged. In the majority of cases the medication prescribed is indeed FDA-approved for opioid use disorder — making the denial factually incorrect and reversible on the administrative record.

Federal law adds additional leverage: the Mental Health Parity and Addiction Equity Act (MHPAEA) prohibits insurers from applying treatment limitations to substance use disorder benefits that are more restrictive than those applied to comparable medical or surgical benefits.

## Federal Appeal Framework

• Internal appeal (Level 1): Must be filed within the timeframe stated in your denial letter (typically 180 days for ACA-regulated plans, 60 days for many ERISA plans). Aetna must respond within 30 days for non-urgent requests, 72 hours for urgent/expedited.
• External review (ACA §2719 / ERISA §503): If the internal appeal is denied, you have the right to an independent external review. The federal window is generally up to four months from the final internal denial, though state deadlines may be shorter — check your denial letter. An accredited independent review organization (IRO) examines the case de novo.
• Expedited option: If the standard timeline would seriously jeopardize your health, request expedited review; decisions are required within 72 hours.

## Concrete Appeal Steps

1. Request the complete claim file and Aetna's clinical coverage policy for buprenorphine MOUD in writing. 2. Obtain a letter from your prescriber confirming the exact product name, NDC, and its FDA-approved indication for opioid use disorder. 3. Include the FDA approval documentation (the drug label is publicly available on the FDA website) to demonstrate the product is approved for the indication billed. 4. Submit a MHPAEA parity argument if Aetna cannot show equivalent scrutiny is applied to comparable medical treatments. 5. If the internal denial is upheld, file immediately for external review.

## Documentation to Gather

• Diagnosis of opioid use disorder confirmed in the medical record
• Prescribing clinician's letter of medical necessity identifying the FDA-approved product and indication
• FDA prescribing information (label) for the specific sublingual buprenorphine product
• Prior treatment history relevant to opioid use disorder, with dates and outcomes
• Any MHPAEA comparative-benefit analysis you can request from Aetna

## Criteria-Mapping Structure

For each requirement Aetna cites in the denial, pull the corresponding chart fact:

| Aetna Requirement | Your Supporting Evidence | |---|---| | FDA-approved indication | Prescriber letter + FDA label confirming approval for OUD | | Correct product code billed | EOB/claim detail vs. NDC on the label | | Treating diagnosis matches indication | ICD-10 code in chart vs. label indication statement |